Friday, December 12, 2025 12/12/2025

Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling

Award Number: R01CA278971
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/29/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2028

Group Awards By:

View Award Description

Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling - PROJECT SUMMARY/ABSTRACT Esophageal squamous cell carcinoma (ESCC) accounts for over 80% of esophageal cancer cases and has a poor prognosis, largely due to the absence of symptoms in the early stages. Although an early diagnosis of ESCC may lead to better outcomes in treatment, early detection is challenging since ESCC originates from the basal cell layer and invades the lamina propria. Therefore, understanding the biology of ESCC initiation and developing model systems that recapitulate ESCC neoplasia is crucial. Currently, the mechanism of ESCC initiation and immune landscape remodeling during ESCC initiation and tumorigenesis remain unclear. We have established a genetically engineered murine esophageal organoid model system that has shown significant potential to study ESCC initiation. Through CRISPR-based genetic manipulation of murine esophageal organoids, we identified the key tumor suppressor genes most frequently deleted in ESCC patients and established 32 esophageal organoid lines. Transcriptomics of the neoplastic organoids indicated a transcriptional signature consistent with ESCC patients, and single-cell transcriptomics identified distinct cell lineage, multiple root cells, and critical regulons of such neoplastic organoids. Interestingly, only specific neoplastic organoid- derived cells developed tumors in immunocompetent mice. Our preliminary results suggest that the loss of tumor suppressor genes is a crucial event for ESCC initiation by inducing esophageal neoplasia (cell-autonomous) and remodeling the immune landscape (non-cell-autonomous). Therefore, we hypothesize that the combinatorial loss of tumor suppressor genes initiates ESCC by inducing esophageal neoplasia, cell plasticity, and immune evasion. This hypothesis will be tested through two specific aims: Aim 1. To determine the genetic and transcriptional network initiating ESCC using new model systems; Aim 2. To determine the impact of targeting the ESCC-driven immune landscape remodeling on ESCC initiation and tumorigenesis. The study will fill the current knowledge gap by unveiling the biology of ESCC initiation and providing new models for developing viable therapeutic applications for early ESCC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $468,540 )
2026	2026	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	3	12/8/2025	NON-COMPETING CONTINUATION	$468,540
														Subtotal = $468,540

Issue Date FY: 2025 ( Subtotal = $520,600 )
2025	2025	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	2	11/7/2024	NON-COMPETING CONTINUATION	$468,540
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	001	2	8/21/2025	NON-COMPETING CONTINUATION	$52,060
														Subtotal = $520,600

Issue Date FY: 2024 ( Subtotal = $623,452 )
2024	2024	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	1	12/29/2023	NEW	$623,452
														Subtotal = $623,452

Grand Total All Awards = $1,612,592

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling

Award Number: R01CA278971

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/29/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer